Acceleron Pharma Inc (NASDAQ:XLRN) has received an average recommendation of “Buy” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $56.20.

A number of analysts have issued reports on the company. BidaskClub downgraded Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Saturday, December 8th. HC Wainwright reissued a “buy” rating and issued a $72.00 target price on shares of Acceleron Pharma in a report on Monday, December 3rd. reissued a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, November 28th. Finally, Piper Jaffray Companies raised Acceleron Pharma from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $52.00 to $75.00 in a report on Monday, September 17th.

XLRN traded down $1.09 on Friday, hitting $46.96. 8,979 shares of the company were exchanged, compared to its average volume of 439,869. Acceleron Pharma has a twelve month low of $32.53 and a twelve month high of $59.59. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -17.57 and a beta of 1.39.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.03. The firm had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $4.37 million. Acceleron Pharma had a negative return on equity of 32.69% and a negative net margin of 807.36%. Acceleron Pharma’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.65) EPS. As a group, equities research analysts anticipate that Acceleron Pharma will post -2.51 EPS for the current year.

In related news, CEO Habib J. Dable sold 12,675 shares of the stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $52.99, for a total value of $671,648.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin F. Mclaughlin sold 5,712 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $42.80, for a total value of $244,473.60. Following the completion of the transaction, the chief financial officer now directly owns 42,527 shares in the company, valued at $1,820,155.60. The disclosure for this sale can be found here. Insiders have sold a total of 32,074 shares of company stock worth $1,504,108 in the last quarter. 3.00% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of XLRN. Rhumbline Advisers increased its holdings in Acceleron Pharma by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 38,122 shares of the biopharmaceutical company’s stock valued at $1,850,000 after purchasing an additional 1,268 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Acceleron Pharma by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 171,104 shares of the biopharmaceutical company’s stock valued at $8,302,000 after acquiring an additional 5,028 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Acceleron Pharma by 6.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 205,240 shares of the biopharmaceutical company’s stock valued at $9,959,000 after acquiring an additional 12,969 shares in the last quarter. BlackRock Inc. grew its stake in shares of Acceleron Pharma by 4.3% during the second quarter. BlackRock Inc. now owns 4,205,069 shares of the biopharmaceutical company’s stock valued at $204,030,000 after acquiring an additional 175,010 shares in the last quarter. Finally, Glen Harbor Capital Management LLC grew its stake in shares of Acceleron Pharma by 12.4% during the second quarter. Glen Harbor Capital Management LLC now owns 19,482 shares of the biopharmaceutical company’s stock valued at $945,000 after acquiring an additional 2,142 shares in the last quarter. 95.78% of the stock is currently owned by institutional investors and hedge funds.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Story: Conference Calls and Individual Investors

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.